Stock-based Compensation (Tables)
|
9 Months Ended |
Jun. 30, 2026 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| Summary of Stock-Based Compensation Expenses |
Total stock-based compensation expense recognized were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Nine months ended June 30, | | (in thousands) | | 2026 | | 2025 | | 2026 | | 2025 | | Cost of revenues | | $ | 1,480 | | | $ | 2,061 | | | $ | 4,447 | | | $ | 5,340 | | | Research and development | | 1,700 | | 921 | | 5,436 | | 7,188 | | Selling, general and administrative | | 14,996 | | 13,075 | | 40,502 | | 35,848 | | Total stock-based compensation expense | | $ | 18,176 | | | $ | 16,057 | | | $ | 50,385 | | | $ | 48,376 | |
|
| Summary of Nonvested Restricted Stock Units Activity |
A summary of the Company’s restricted stock unit activity excluding the performance-based restricted stock units during the nine months ended June 30, 2026 was as follows:
| | | | | | | | | | | | | | | | (in thousands, except per share data) | | Shares | | Weighted average grant date fair value per share | | Nonvested shares at September 30, 2025 | | 1,882 | | $ | 37.21 | | | Granted | | 1,647 | | 32.92 | | Vested/Issued | | (772) | | 34.95 | | Forfeited | | (154) | | 37.23 | Nonvested shares at June 30, 2026 | | 2,603 | | $ | 35.17 | |
|
| Summary of Nonvested Performance-based Units Activity |
A summary of the Company’s performance-based restricted stock units activity during the nine months ended June 30, 2026 was as follows: | | | | | | | | | | | | | | | | (in thousands, except per share data) | | Shares | | Weighted average grant date fair value per share | | Nonvested shares at September 30, 2025 | | 1,934 | | $ | 37.85 | | | Granted | | 961 | | 27.58 | | Vested/Issued | | (419) | | 22.10 | | Forfeited | | (82) | | 42.86 | Nonvested shares at June 30, 2026 | | 2,394 | | | $ | 36.32 | |
|
| Summary of Activity Under Option and Performance Stock Options |
A summary of the Company’s options including the performance-based stock options during the nine months ended June 30, 2026 was as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | (in thousands, except per share and contractual term data) | | Shares | | Weighted average exercise price per share | | Weighted average remaining contractual term (years) | | Aggregate intrinsic value | | Outstanding at September 30, 2025 | | 1,276 | | | $ | 30.80 | | | 3.59 | | $ | 6,616 | | | Forfeited | | (7) | | | 43.42 | | — | | | — | | | Exercised | | (270) | | | 21.75 | | — | | | 10,767 | | Outstanding at June 30, 2026 | | 999 | | | $ | 33.15 | | | 2.91 | | $ | 70,282 | | Vested and exercisable at June 30, 2026 | | 999 | | | $ | 33.15 | | | 2.91 | | $ | 70,282 | |
|
| Summary of Stock Option Valuation Assumptions |
The number of shares of the Company's common stock reserved for issuance under the 2018 Employee Stock Purchase Plan ("ESPP") as of June 30, 2026 was as follows: | | | | | | | | | | (in thousands) | | Shares
available | As of September 30, 2025 | | 716 | | Additional shares authorized | | 249 | | Shares issued during the period | | (104) | | As of June 30, 2026 | | 861 |
|